The lancet. Diabetes & endocrinology

The most recent articles from: Lancet Diabetes Endocrinol November 2013

Lancet Diabetes Endocrinol · Nov 2013

Randomized Controlled Trial Multicenter Study

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

We aimed to investigate the efficacy and tolerability of empagliflozin, an oral, potent, and selective inhibitor of sodium-glucose co-transporter 2, in patients with type 2 diabetes who had not received drug treatment in the preceding 12 weeks. ⋯ Boehringer Ingelheim and Eli Lilly.

read more… mark as read…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,706,642 articles already indexed!